Skip to main content

Articles By Kathryn H. Dao, M.D.

Plaquenil.HCQ_.pills_.jpg (keep)

Prolonging the Controversy of Hydroxychloroquine

By Kathryn H. Dao, M.D.
30 November 2021

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.

Read Article
Couple walking on beach with dog

Redefining Aging

By Kathryn H. Dao, M.D.
17 November 2021

I was thrilled that the American College of Rheumatology put together the Community Aging Hub and multiple sessions to help rheumatologists identify gaps in care for older patients with rheumatic diseases. My friend and colleague, Dr. Una Makris, taught me the 5 M’s of aging that should be assessed in our patients.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Prolonging the Controversy of Hydroxychloroquine

By Kathryn H. Dao, M.D.
05 November 2021

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19.

Read Article
interview,magnify,woman

Interview Season

By Kathryn H. Dao, M.D.
20 September 2021

We are at that time of year when rheumatology fellowship programs across the nation are exploring potential candidates to train. Program directors work hard to attract the finest candidate, hoping to shape a future leader; applicants want to impress programs with their experience and desire a place where opportunities are available to explore their potential. So how does a program choose from a large pool of qualified applicants to fill just a few seats? What should applicants look for in a program to ensure a good fit? 

Read Article
lupus.jpg

How Do You Measure Success When It Comes to SLE?

By Kathryn H. Dao, M.D.
10 June 2021

EULAR 2021 opened with a grand debate to answer this essential question:  should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?  

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Combination vs. Sequential Therapy for the Treatment of Lupus Nephritis

By Kathryn H. Dao, M.D.
08 June 2021

Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response. 

Read Article
Meeting audience conference

Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights

By Kathryn H. Dao, M.D.
24 March 2021

In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning. In the Day 1 learning pods, the audience was given a tour of the new drugs in development for RA.

Read Article
gavel judgement decide gold

Rebuttals

By Kathryn H. Dao, M.D.
15 March 2021

Since the COVID vaccine rollout, more people have been eligible to receive the vaccine. However, not everyone chooses to get one. I have heard many reasons (aka excuses) from my patients who are vaccine hesitant. 

Read Article
covid vaccine

Best of 2020: My Experience as a COVID19 Vaccine Trial Participant

By Kathryn H. Dao, M.D.
28 December 2020

I have been an investigator for many clinical rheumatology studies over the past two decades but have never been a study subject until now. On October 31, 2020, I enrolled in the phase 3 trial of the Pfizer/BioNTech mRNA vaccine against SARS-CoV2 (protocol C4591001). Here's my experience.

Read Article
registry.jpg

Best of 2020: The COVID-19 Global Rheumatology Registry

By Kathryn H. Dao, M.D.
24 December 2020

What started out as online tweets and sharing newsfeed and case reports, has progressed to the formation of the COVID-19 Global Rheumatology Alliance, whose mission is to create an international rheumatology registry of patients affected by the disease in order to better understand the disease and guide clinicians in assessing and treating patients. 

Read Article
×